(Total Views: 912)
Posted On: 07/30/2023 12:35:40 PM
Post# of 153903
article in the WSJ about Biogen buying Reata Pharmaceuticals. They paid over 7 billion - and i think it said Reata is expected to do 1 billion in revenue - but not until 2028.
so, that's 7X revenue from 2028 - and their indications are for rare disease, so not very big markets at all. just shows you - if we can just get our #$%& together, our valuation should soar.
TO DO ITEMS:
1. hire impressive, business-minded CEO
2. get hold lifted
3. ink partnerships
4. sell for +$10
so, that's 7X revenue from 2028 - and their indications are for rare disease, so not very big markets at all. just shows you - if we can just get our #$%& together, our valuation should soar.
TO DO ITEMS:
1. hire impressive, business-minded CEO
2. get hold lifted
3. ink partnerships
4. sell for +$10
(16)
(0)
